Učitavanje...
Diffuse pulmonary lymphangiomatosis treated with bevacizumab
Diffuse pulmonary lymphangiomatosis (DPL) is a rare disease caused by uncontrolled lymphatic vessel proliferation resulting in respiratory dysfunction. Lymphatic vessel growth is influenced by vascular endothelial growth factor (VEGF). It has been shown that bevacizumab, a monoclonal antibody to VEG...
Spremljeno u:
| Izdano u: | Respirol Case Rep |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Ltd
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6260917/ https://ncbi.nlm.nih.gov/pubmed/30510764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.384 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|